US cancer biomarker market 2011 - 2021 brochure

United States Cancer BiomarkerMarket Opportunities , 2011 – 2021

P h a r m a & H e a l t h c a r e C o n s u l t a n t s

2

P r o d u c t O v e r v i e w

As per the National Institutes of Health Biomarkers Definitions Working Group, a biomarker is defined as “a characteristic

that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or

pharmacologic responses to a therapeutic intervention”.

Cancer Biomarker can be Ribo-nucleic Acid (RNA), Deoxyribose Nucleic Acid (DNA),

Messenger RNA (mRNA), Proteins, Metabolites, etc.

The markers are produced either by tumor itself or by any other tissues as a response

to the presence of cancer.

© Pharmaion

Cancer Biomarkers can be found in differing types of body fluids, tissues and cells. They are used for screening the general population, differential diagnosis of cancer in

symptomatic patients, clinical staging of cancer, estimating the tumor growth, evaluate response of treatment, disease recurrence, etc.

3

© Pharmaion

T a b l e o f C o n t e n t s

S No. Contents

1. Product Overview

2. Research Methodology

3. Analyst View

4. Global Cancer Biomarker Market Overview

5 United States Cancer Biomarker Market Overview

6. United States Cancer Biomarker Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1.By Profiling Technology (Immunoassay, Omics Technology, Cytogenetic Technology,Imaging Technology & Bioinformatics)

6.2.2.By Application (Drug Discovery and Development, Diagnosis, Prognostics, RiskAssessment & Others)

6.2.3.By End User (Contract Research Organizations (CROs) and Drug Manufacturers, &Healthcare Providers)

6.2.4. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, & Others)

6.2.5. By Region

6.2.6. By Company

7. United States Cancer Biomarker Immunoassay Profiling Technology Market Outlook


7.1.1. By Value


4


S No. Contents

7.2.1.By Type (Immunohistochemistry (IHC), Enzyme–linked Immunosorbent Assay(ELISA) & Flow Cytometry)

8. United States Cancer Biomarker Omics Profiling Technology Market Outlook


8.1.1. By Value


8.2.1. By Type (Genomics, Proteomics & Others)

9. United States Cancer Biomarker Cytogenetic Profiling Technology Market Outlook


9.1.1. By Value


9.2.2. By Type (Fluorescent In-situ Hybridisation (FISH) & Others)

10. United States Cancer Biomarker Imaging Profiling Technology Market Outlook

10.1 Market Size & Forecast

10.1.1. By Value


10.2.1.By Type (Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), Computed Tomography (CT) & Others)

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends and Developments

12.1. Involvement of Biomarker in Personalised Medicine

12.2. Biomarkers as Surrogate Endpoints © Pharmaion

5


S No. Contents

12.3. New Product Developments

12.4. Prognostic and Predictive Biomarker Test for Breast Cancer

12.5. Product Enhancements

13. Policy and Regulatory Landscape

14. United States Economic Profile

15. Competitive Landscape

15.1. Abbott Laboratories

15.2. Affymetrix, Inc.

15.3. Roche Diagnostics Corporation

15.4. Illumina, Inc.

15.5. Hologic, Inc.

15.6. Merck & Co. Inc.

15.7. Agilent Technologies

15.8. Qiagen Sciences, Inc.

15.9. Becton, Dickinson and Company

15.10 Alere, Inc.

16. Strategic Recommendation

17. About Us & Disclaimer

© Pharmaion

6

R e s e a r c h M e t h o d o l o g y

Primary Research

•Identifying Key Opinion Leaders

•Questionnaire Design

•In-depth Interviews

•Coverage across Value Chain market

Market Estimation & Forecasting

Bottom-Up or Top-down approach for Market size estimation

Historical trend examination

Impact analysis of drivers and challenges to market growth

Statistical evaluation to develop the actual forecast

Data Validation, Analysis and Interpretation

Data validation through Primary & Secondary outreach, data analysis and interpretation of key findings

Preliminary Data Mining

Qualitative and Quantitative research

2016E 2017F 2018F 2019F 2020F 2021F

CAGR (2016E-2021F): XX%

United States Cancer Biomarker Market Opportunities, 2011 - 2021

Secondary Research

•Government websites

•Company annual reports

•White papers

•Investor presentation

•Financial reports

© Pharmaion

7

© Pharmaion

I n d u s t r y B r i e f

Cancer Biomarker Market in US to reach $ 18 billion by 2021

Growing incidence of cancer, increasing government funding for cancer research coupled with rising trend ofpersonalised medicine to drive United States cancer biomarker market through 2021

According to Pharmaion report, “United States Cancer Biomarker Market Opportunities, 2011 – 2021”, thecancer biomarker market in the United States is projected to stand at around US$ 18 billion by 2021. In theUnited Sates, the prevalence rate of cancer is increasing at a robust pace on account of various factors such asgrowing consumption of alcohol, high smoking prevalence, poor dietary habits and sedentary lifestyle of thecitizens. Moreover, certain people inherits faulty genes, which also increases the risk of cancer.

In January 2016, National Institute of Health (NIH) announced a funding opportunity for integrating multiplexedbiomarker approaches into a singular complementary method to improve cancer screening and early detection ofdifferent types of cancers. Moreover, various pharmaceutical companies are collaborating to develop novel cancerbiomarkers to address the unmet demand for personalised medicine. Backed by increasing government fundingfor cancer biomarker research coupled with increasing use of biomarkers in drug discovery development andclinical trials, the United States cancer biomarker market is projected to witness a healthy growth rate duringforecast period.

In terms of profiling technology, the market has been segmented into five broad categories, namelyImmunoassay, Omics Technology, Cytogenetic Technology, Imaging Technology and Bioinformatics. Out of thesecategories, Immunoassay segment dominated the overall market of cancer biomarker in the United States in2015. Being a traditional biomarker profiling technique, it is the most recommended test by oncologists inhospitals and independent laboratories. However, the Omics Technology is forecast to grow at the highest rateduring 2016 – 2021. Contract Research Organizations (CROs) and drug manufacturers are the major end users ofcancer biomarkers in the US on account of high number of clinical research studies on cancer patients andgrowing demand for high quality cancer biomarker testing using advanced tumor profiling technologies.

“Biomarkers are integrated into drug development programmes, starting from cancer identification to validationof clinical practice. Ability of biomarkers to predict drug efficacy rapidly than the conventional clinical endpointshelps in substantially augmenting the product development in certain cancer areas. Backed by variousapplications and advantages, the overall cancer biomarker market in the United States would continue to exhibitpromising growth over the next five years. However, high cost of biomarker testing, especially next-generationsequencing for cancer diagnosis, is anticipated to pose a major challenge.” said Mr. Karan Chechi, ResearchDirector with Pharmaion Consultants, a research based global management consulting firm focused on pharmaand healthcare industry.

http://www.pharmaion.com/report/united-states-cancer-biomarker-market-opportunities-2011--2021/60.html

8

S a m p l e D a t a - S n a p s h o t

10 20 30 40 50 60 70 80 90 100 110

2011 2012 2013 2014 2015 2016E2017F2018F2019F2020F2021F

United States Cancer Biomarker Market Size,

By Value, 2011-2021F (USD Billion)

© Pharmaion

United States Cancer Biomarker Market Share, By

Profiling Technology, By Value, 2011-2021F

2% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2%

19% 19% 19% 19% 19% 19% 19% 19% 19% 19% 19%

22% 22% 22% 22% 22% 22% 22% 22% 22% 22% 22%

30% 30% 30% 30% 30% 30% 30% 30% 30% 30% 30%

27% 27% 27% 27% 27% 27% 27% 27% 27% 27% 27%

2011 2012 2013 2014 2015 2016F 2017F 2018F 2019F 2020F 2021F

Immunoassay

OmicsTechnology

CytogeneticsTechnologyImagingTechnology

10 20 30 40 50

20112012201320142015

North-East Region

10 20 30 40 50

20112012201320142015

West Region

10 20 30 40 50

2011 2012 2013 2014 2015

Midwest Region

10 20 30 40 50

20112012201320142015

South Region

United States Cancer Biomarker Market Size, By

Region, By Value, 2011-2015 (USD Billion)

100200

300400

500

CMC Non ClinicalResearch

ClinicalResearch

Appliedresearch

Other

United States Number of Contract Research

Organisations (CROs), By Type, 2012

United States Estimated Number of New Lung &

Bronchus Cancer Cases, By Sex, 2015 & 2016F

200300

400

100 150 200

Both Sex Male Female

2015

2016F

Abbott …

Affymetrix Inc, …Roche Diagnostics Corporation, 25%

Others, 25%

Abbott Laboratories,

25%

Affymetrix Inc, 25%Roche Diagnostics Corporation, 25%

Others, 25%

United States Cancer Biomarker Market Share,

By Company, By Value, 2015 & 2021F

R e p o r t O r d e r i n g

To View Sample OR Purchase Report

Report Price

Report Name: United States Cancer Biomarker Market

Opportunities, 2011 – 2021

License Type Price

Single User License $2500

Single User License Print $3000

Enterprise License $5000

9



10

A b o u t U s & D i s c l a i m e r

NORTH AMERICA

Pharmaion Consultants LLC

708 3RD Avenue, 6th Floor, New York, NY,

United State, 10017

[email protected]

+1 646 862 0089

www.pharmaion.com

About Us:

Pharmaion is a research based management consulting firm focused exclusively on Healthcare & Pharmaceutical industry.

Pharmaion’s core values are value, integrity and insight. Led by a team of dynamic industry experts, Pharmaion provides itscustomers with high value market research and advisory services that helps them identify new market opportunities, growthengines and innovative ways to capture the market share. As a result, Pharmaion’s clients lead rather than follow markettrends. Not bound by legacy, Pharmaion’s cutting-edge research model leverages its decades of research knowledge and anincreased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditionalmarket research, Pharmaion’s reports do not just deliver data and knowledge rather highlights the insights in a more usable andinteractive format for its clients.

Pharmaion is committed to assisting customers worldwide with their unique market research needs by providing them withcomprehensive, value-added solutions and professional market intelligence services. Pharmaion employs the industry’s best-trained industry Analysts and Consultants, which advises and assists customers in meeting their full service market researchand consulting requirements.

Related Reports

United States Breast Pumps Market Opportunities, 2011 – 2021

United States Disposable Syringe Market Opportunities, 2011 - 2021

Global Tissue Engineered Medical Device Market Forecast & Opportunities, 2020

Disclaimer:

The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation ismade that it is timely, accurate or complete. Pharmaion Consultants has taken due care and caution in compilation of data as this has beenobtained from various sources including which it considers reliable and first hand. However, Pharmaion Consultants does not guarantee theaccuracy, adequacy or completeness of any information and it is not responsible for any errors or omissions or for the results obtained from theuse of such information and especially states that it has no financial liability whatsoever to the subscribers / users of this report. Theinformation herein, together with all estimates and forecasts, can change without notice. All the figures provided in this document are indicativeof relative market size and are strictly for client’s internal consumption. Usage of the same for purpose other than internal will require priorapproval of Pharmaion Consultants.

ASIA-PACIFIC

Pharmaion Consultants Pvt. Ltd.

A – 51, Sector 57, Noida, National Capital Region,

India - 201301

[email protected]

+91 - 120 - 452 3900

www.pharmaion.com © Pharmaion

US cancer biomarker market 2011 - 2021 brochure

Business

Transcript of US cancer biomarker market 2011 - 2021 brochure